


Corporate Presentation

May, 2015

For personal use only



- > Sleep Diagnostics & Treatment
- > Neuro Diagnostics
- > Brain Research
- > Ultrasonic Blood Flow Monitoring

Investor Overview

Core business: returned to growth.

Neurology growth opportunity: New market for CMP. We have the leading brain source localisation software.

- Asian EEG - largest segment of \$886.8 m brain monitoring device market
- Asian EEG - 2013 \$81.8m PA to 2018 \$133.0m by 2018, CAGR: 10.40% (1)

Trend towards Home Sleep Testing (HST) - CMP well positioned – growing market (2)(3)

eHealth: Moving Compumedics' proprietary technology to the cloud. \$10m of contracts already won.

Spin offs/strategic decisions to unlock significant value for shareholders


FY15 guidance: \$33m sales, revenue growth >10%, EBITDA \$3.5-4m, NPAT \$1.8-\$2m.

Who is Compumedics?

- **Compumedics** is a leading global, innovative developer and manufacturer of medical devices for:
 - Diagnosing sleep disorders
 - Monitoring neurological disorders including long-term epilepsy monitoring (LTEM)
 - Highly sophisticated brain research
 - Ultrasonic monitoring of blood flow through the brain (Transcranial Doppler [TCD])
- **Compumedics** is a technological leader in its chosen markets:
 - #1 Australia sleep & neuro diagnostics device supplier
 - #1 Japan sleep diagnostics device supplier
 - #1 China sleep diagnostic device supplier to China's premier facilities & #1 TCD device supplier
 - #3 USA sleep diagnostic device supplier and emerging #3 supplier for neurological monitoring devices
- **Compumedics** has a rich intellectual property portfolio
- **Compumedics** e-Health platform is the next growth phase in the company's development
- **Compumedics** listed ASX Dec 21, 2000

Directors & Executive Team Key Management

For personal use only



A Tradition of Innovation

For personal use only



S Series
1987



P Series
1994



Siesta
2000



Somté
2001



SynAmps2
2003



Comperio DQ
2004



Summit IP
2005



Siesta 802
2005



Neuvo LTM
2007



Somté PSG
2006



SynAmpsRT
2008



CURRY6
2009



Somnilink SPAP
2010



Grael HD
2010



Somté PSG 2.0
2011



Somfit
2015

Established Client Profile

For personal use only



National Aeronautics and Space Administration



MAYO CLINIC
College of Medicine

STANFORD UNIVERSITY



UNIVERSITY OF MICHIGAN



Royal Perth Hospital
COMMITTED TO EXCELLENCE



ST VINCENT'S
HEALTH



THE UNIVERSITY OF TOKYO



Peking University



Hennepin County Medical Center
HCMC



Maine Medical Center
centered around you



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



The **Royal Children's**
Hospital Melbourne



YALE UNIVERSITY
SCHOOL OF MEDICINE



Providence
Medical Center

*Sisters of Charity of Leavenworth
Health System*



For personal use only

Core Sleep and Brain Diagnostic Monitoring Business









Core Business Overview

- Core business has now recovered post GFC and high AUD
- We continue to transition product manufacturing and assembly offshore, which will result in reducing the cost of manufacturing to between 1/3 and 1/2 while maintaining premium functionality
- We have traditionally targeted the premium end of the market, which was hit hard by the GFC. We can now target the mass market.
- CMP will be a market disruptor for the first time in its history
- 20,000 installed systems worldwide. Strong brand name and reputation.
- Expecting average sales growth >10% pa

Product Matrix

For personal use only


Product		Used for	Bought by	Average selling price
Grael		Sleep and neurology	Hospitals, doctors and service providers	USD17,500
Somte PSG		Sleep	Hospitals, doctors and service providers	USD10,000
Siesta		Sleep and neurology	Hospitals, doctors and service providers	USD18,000
Neuvo LTM		Neurology	Hospitals, doctors and service providers	USD35,000
Synamps RT		Brain Research	Universities and teaching hospitals	USD38,000
CURRY		Brain research and neurology	Universities, teaching hospitals and regular hospitals	USD20,000

Revenue Composition at ≈\$15.6m


31 December 2014

For personal use only

By geographic region



By product/market



Software upgrades 5 to 10% of system sales


Compumedics sells directly to end-user customers in Australia, USA and Germany and through its network of more than 50 distributors to all other parts of the world

Historical First Half Revenues

6 months to 31 December

For personal use only

Shipped and invoiced




Historical First-Half Earnings

6 months to 31 December


For personal use only

NPAT



■ NPAT ■ F'Cast NPAT

EBITDA



■ EBITDA ■ F'Cast EBITDA


Full year EBITDA for FY2015 is estimated between \$3.5m and \$4.0m. Excluding Medical Innovation costs EBITDA is estimated between \$4.5m to \$5.0m

Employee Composition at ≈130 staff


31 December 2014

For personal use only

By geographic region





By function



Compumedics has its Head Office in Melbourne, Australia with additional offices in Charlotte (NC), USA and Singen, Germany

Tide turning post GFC and high AUD

For personal use only



Growth Drivers – Core business


- Compumedics/NeuroScan LTEM innovative brain analysis software and high performance amplifiers are unrivalled world class technology
- We have >20,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedics.
- Trend towards Home Sleep Testing (HST) – Compumedics well positioned
- Asia Expansion – emphasis on China through our unique and long established relationships there
- Grow sleep diagnostic market position in the US by continuing to expand direct sales force
- Continuing to grow and expand our European business, with emphasis on Germany
- We are the only competitor left who can rival the largest player – Natus Medical

Growth Strategies – core business

USA Clinical Sales Force Expansion


**More sales representatives > more revenue
for both sleep and neurology**

Past



USD4.5m

FY2014 - Now



USD8.0m

FY2016



USD12.5m

FY2017



USD15.5m

For personal use only

China - We are the number 1 Premier Supplier


Compumedics Clients in China

For personal use only

-  Sleep
-  Neuroscience
-  Neuroscan

“Compumedics is the number 1 supplier of premier sleep diagnostics in China”

China Sales – USD’s



“Compumedics is the preferred supplier for an increasing number of leading researchers, universities and hospitals around the world. Compumedics equipment is installed in a number of highly acclaimed medical centers globally and is the provider of choice in over 200 locations in mainland China”

28² XinJiang



Earnings improvement activities

- Outsourcing Manufacturing – lower cost regions of China and Taiwan
- EEG cap production completely relocated at Dec 14 and Grael and Somte production to be completed by July 2015
- Offshore purchasing houses to increase quality and drive down costs. Grael and Somte purchasing relocation complete April 2015
- Streamlining of logistics (final product assembly, testing and shipment) as the business grows
- Completed redesign of all major product lines for aggressive global full market access - based on at least halving cost of goods but retaining quality and performance
- New generation Grael to be released for sale June 2015
- These benefits will start to flow through in FY16 and beyond

For personal use only

Strategic Value Realisation



Strategic value realisation

The company is currently considering options to simplify its business and unlock significant value for shareholders by:

- Spinning out its Germany based DWL Transcranial Doppler (TCD) ultrasound blood flow business
- Spinning out its Brain Research business (NeuroScan)

For personal use only

DWL Spin out opportunity

- DWL is the founding business and global leader in TCD ultrasound.
- Short term growth opportunities in 3D Transcranial Colour Doppler (TCCD)/Duplex Imaging
- Medium term growth opportunities in TBI and Stroke Market
- 3D TCCD is a US\$900m vs DWL's current market of \$US30m. Relatively small investment required in upgrading the user interface to be able to play in this market.
- Traumatic Brain Injury (TBI) – DWL work with some of the world's most respected researchers.
- 3D TCCD and TBI are beyond the current financial capability of DWL. Growth capital needed for this business.
- The potential listing/spin off of DWL based on revenue multiples of comparable listings:
 - - Revenue of \$US6m (based on 4x current revenue) = \$US24m
 - - **Valuing a 30% stake (assuming CMP spin off 70%) in the new entity of US\$7.2m and US\$16.8m of cash freed up for investment in growth of Compumedics and potential returns to shareholders**

Brain Research Spin Out Opportunity

- Enormous neurology devices demand – est. \$7bn pa by 2017 up from \$2bn in 2010
- Growth outlook – significant for Neuroscan CURRY – World's best of class brain analysis software
- CURRY multi modal brain analysis technology – traditional research market - \$50m pa
- CURRY – multi modal brain analysis monitoring – new imaging market - \$4bn pa
- CURRY – MEG Imaging – currently the preferred solution
- NeuroScan/CMP – 9% revenue growth expected. EBITDA approx. \$1.1m
- Similar AIM IPO comparables – post money 5x revenue market capitalization
- **Would unlock significant value, fund growth initiatives and potentially allow a capital distribution to shareholders**

eHealth – Next Phase in Compumedics Growth



Medical Innovations – eHealth

- Compumedics is developing eHealthMedics, an online professional sleep services platform
- Sleep diagnostics is traditionally delivered as a lab-based (equipment intense) or Home Sleep Testing service eHealthMedics has re-architected its solution such that the sleep monitoring and algorithms that translate the raw data into sleep stages run on the cloud, so that all that is required on-site is a mobile sleep system to buffer and transfer the raw data
- The platform is based on Compumedics' core world-class sleep diagnostic technology, built up over more than two decades and \$100m+ in accumulated R&D and \$500m+ in total system sales
- eHealthMedics will provide the backbone and infrastructure to professional sleep service providers

eHealthMEDICS - Competitive Advantage

For personal use only

- The scalability and cost efficiencies of eHealthMedics vs traditional sleep diagnostics allow the service to accommodate very large sleep-disordered populations, even in regions where private or public health insurance is limited or non-existent (eg China – a key market for eHealthMedics)
- The numerous validated and proven algorithms & report templates have been developed over 25+ years of ongoing R&D – they cannot be replicated
- Compumedics possess a broad spectrum of medical diagnostic and monitoring technologies that are unrivalled globally
- These technologies have served clients including NASA, Stanford, Mayo Clinic, Yale, Beijing University, University of Tokyo and a range of leading hospitals worldwide, as well as provided the infrastructure for the worlds largest home based sleep study and database of its kind – the USA National Institute of Health’s ‘Sleep Heart Health Study’
- The above provides eHealthMedics with the ability to leverage existent proven systems and relationships into the professional sleep services space with “gold standard”, regulatory approved and certified diagnostic technology backed by key opinion leaders within the industry

eHealthMEDICS – Making Progress

- eHealthMedics has already locked in excess of \$10m of forward orders over the next three years (primarily in China) for its professional services platform. Initial pilot sites commence in May and June this year
- Operational systems have been developed for the cloud based capture, transfer and translation of medical grade sleep parameters from any web-enabled device. The system can then store, analyse and interpret that data in a simple and actionable manner, reducing the need for on-site professionals
- Compumedics are now approaching a select group of strategic partners/investors to expedite the process and rapidly deploy the platform to market
- Key partners being pursued include web, telco, eHealth, consumer health/electronics providers and device manufacturers
- Compumedics will update the market as significant further progress is achieved

eHealthMEDICS - We bring to the table a eHealth services platform that leverages core competencies built over 25 years

mHealth Product Ecosystem: Required Competencies

[traditional business]

est. 1987



- Over 250 product patents
- Established medical credentials - 000s of medical publications / leading R&D team
- Government / regulatory certification and compliance
- Clinical diagnostic software (inc. sleep disorders, neurology, heart, epilepsy, diabetes)
- Medical monitoring devices – home and hospital
- Cloud-based algorithms, data processing and security
- Global Network of Physicians
- Clinical monitoring sensors



- Medical grade 'life-signals' monitoring

Patents / IP

Govt. Funding

- Eligibility for govt. health scheme rebates

Cloud Medical Data Processing

Regulatory Compliance

- Inc. medical data security (FDA, CE, TGA compliant, US HIPPS)

Health Services

- Established global network of Physicians

new mHealth Platform

Clinical Grade Products

- Applications
- Network
- Sensors / wearables

Investor Summary

- Core business returned to growth: FY15: \$33m revenue, >10% sales growth
- Sales force expansion, neurology market opportunity and earnings improvement initiatives to drive growth of core business
- Intense company focus on improving returns to shareholders. Current share price does not reflect the significant value of our company. We believe that in time the share price will reward our efforts and our shareholders
- e-Health platform is the next step for CMP's growth. Moving 25+ years and \$100m+ in cumulative R&D to a modern platform to solve a massive and growing problem. \$10m of contracts already locked in.
- Spin off/strategic decisions to unlock significant value, provide funds for growth and potentially capital returns to shareholders
- FY15 guidance: \$33m revenue, \$3.5-\$4m EBITDA, \$1.8-\$2m NPAT

Thank you

For personal use only



- > Sleep Diagnostics & Treatment
- > Neuro Diagnostics
- > Brain Research
- > Ultrasonic Blood Flow Monitoring